Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.

The Oncologist
Anthony R MatoAndre Goy

Abstract

Although patients with B-cell non-Hodgkin's lymphoma (NHL) usually respond to initial conventional chemotherapy, they often relapse and mortality has continued to increase over the last three decades in spite of salvage therapy or high dose therapy and stem cell transplantation. Outcomes vary by subtype, but there continues to be a need for novel options that can help overcome chemotherapy resistance, offer new options as consolidation or maintenance therapy postinduction, and offer potentially less toxic combinations, especially in the elderly population. The bulk of these emerging novel agents for cancer treatment target important biological cellular processes. Bortezomib is the first in the class of proteasome inhibitors (PIs), which target the critical process of intracellular protein degradation or recycling and editing through the proteasome. Bortezomib is approved for the treatment of relapsed or refractory mantle cell lymphoma. The mechanisms of proteasome inhibition are very complex by nature (because they affect many pathways) and not fully understood. However, mechanisms of action shared by bortezomib and investigational PIs such as carfilzomib, marizomib, ONX-0912, and MLN9708 are distinct from those of other NHL tr...Continue Reading

References

Nov 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert Z OrlowskiSteven L Soignet
Jun 21, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lan V PhamRichard J Ford
Mar 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M JermannR A Stahel
May 4, 2004·Nature Reviews. Cancer·Julian Adams
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andre GoyAlma M Rodriguez
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Owen A O'ConnorAndrew D Zelenetz
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mathias J RummelParis S Mitrou
Aug 12, 2005·Mayo Clinic Proceedings·Stephen M Ansell, James Armitage
Sep 10, 2005·Blood·Lindsay M MortonMartha S Linet
Apr 1, 2006·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Luca Paoluzzi, Owen A O'Connor
Apr 12, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandra J StraussT Andrew Lister
May 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Owen A O'ConnorAsher Chanan-Khan
May 16, 2006·Apoptosis : an International Journal on Programmed Cell Death·Albert F KaboreSpencer B Gibson
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul G RichardsonAnthony A Amato
Sep 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gustaaf W van ImhoffPhilip M Kluin
Sep 7, 2006·Journal of the National Cancer Institute·Yuki IshiiDoris Germain
Sep 15, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A BelchE A Eisenhauer
Sep 27, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard I FisherAndré Goy
Oct 19, 2006·British Journal of Cancer·D ChauhanK C Anderson
Dec 19, 2006·Molecular Cancer Therapeutics·Mark J WilliamsonMark Rolfe
Jan 24, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Gaël RouéDolors Colomer
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N Lynn Henry, Daniel F Hayes
Aug 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pier Luigi ZinzaniMichele Baccarani
Sep 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mitchell R SmithIndira Joshi
Oct 13, 2007·Clinical Lymphoma & Myeloma·Andre Goy, Tatyanna Feldman

❮ Previous
Next ❯

Citations

Oct 19, 2012·Cell Death & Disease·K-S ChanH-Y Li
Oct 2, 2012·The Journal of Clinical Investigation·Pedro JaresElias Campo
Mar 20, 2014·Veterinary Immunology and Immunopathology·Daisuke ItoJaime F Modiano
Nov 11, 2015·Proceedings of the National Academy of Sciences of the United States of America·Chi Keung LamEvangelia G Kranias
Oct 28, 2014·ACS Chemical Biology·Melanie A PriestmanDavid S Lawrence
Nov 21, 2015·Molecular BioSystems·D VergaraM Maffia
Feb 22, 2014·Immunopharmacology and Immunotoxicology·Sufia Butt HassanAnders Elm Pedersen
Sep 30, 2014·Expert Opinion on Pharmacotherapy·Prithviraj BoseSteven Grant
Jan 2, 2014·Biochimica Et Biophysica Acta·Anna Lisa FurfaroMariapaola Nitti
Jul 23, 2016·Expert Review of Hematology·Rebecca CitrinDavid T Teachey
Apr 14, 2017·Hematology/oncology and Stem Cell Therapy·Jose D Sandoval-SusBijal D Shah
Dec 6, 2017·Therapeutic Advances in Hematology·Trent Peng WangStefan Klaus Barta
Apr 6, 2019·Anti-cancer Agents in Medicinal Chemistry·Aimen K AljoundiMahmoud E S Soliman
Jan 23, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Clement Chung
Dec 1, 2015·Neuro-oncology Practice·Wolfgang GrisoldChiara Briani
Aug 22, 2015·Oncotarget·Tatyana A GrigorevaNickolai A Barlev
Jan 23, 2021·Clinical Lymphoma, Myeloma & Leukemia·Swetha KambhampatiCharalambos B Andreadis
Sep 2, 2017·Biochemical and Biophysical Research Communications·Yong-Eun KimKee K Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.